This randomized controlled clinical trial aims to evaluate the effect of orlistat on the metabolic and hormonal features of women with polycystic ovary syndrome (PCOS). Eligible women diagnosed with PCOS according to the Rotterdam criteria will be randomly assigned to receive either orlistat plus standard lifestyle advice or placebo plus standard lifestyle advice for three months. The study will assess the effect of orlistat on hormonal parameters, glucose metabolism, lipid profile, liver function, anthropometric measures, non-alcoholic fatty liver disease, and quality of life to determine its effectiveness as an adjunctive treatment for women with PCOS.
Age range
18 Years – 45 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Polycystic Ovary Syndrome (PCOS) Features
Timeframe: Baseline and 3 months
Luteinizing Hormone/Follicle Stimulating Hormone (LH/FSH) Ratio
Timeframe: Baseline and 3 months
Anti-Müllerian Hormone (AMH)
Timeframe: Baseline and 3 months
Follicle Stimulating Hormone (FSH)
Timeframe: Baseline and 3 months
Luteinizing Hormone (LH)
Timeframe: Baseline and 3 months
Free Testosterone
Timeframe: Baseline and 3 months
Fasting Blood Glucose
Timeframe: Baseline and 3 months